Introduction to Poseida Therapeutics Inc. (350+ Words)

Poseida Therapeutics Inc. is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to developing life-saving cell and gene therapies for patients with cancer and rare diseases. As a leader in the Healthcare and Biotechnology sectors, Poseida combines its proprietary gene editing platforms—piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing, and Booster Element—to create next-generation allogeneic CAR-T cell therapies that are more durable, safer, and scalable. The company’s mission is to revolutionize the treatment of hematologic malignancies and solid tumors by overcoming the limitations of current autologous therapies.

With a robust pipeline including P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors, Poseida has attracted significant partnerships, notably with Roche and Novartis, validating its technology and market potential. The company’s reputation is built on scientific excellence, transparency, and a patient-first approach, making it a top employer for scientists and professionals seeking to impact the future of medicine. Organizations ranging from academic medical centers to global pharmaceutical firms rely on Poseida’s platforms for collaborative research and licensing opportunities.

Company History and Business Evolution (450+ Words)

Founded in 2014 by a team of leading scientists including Dr. Matthew Scholz (CEO until 2021) and Dr. Eric Ostertag (CSO), Poseida Therapeutics emerged from the acquisition of transposon-based gene therapy assets from Transposagen Biopharmaceuticals and Chrysalis Biotherapeutics. The company’s early development focused on harnessing the piggyBac transposon system to efficiently insert large genetic payloads into T cells, enabling the creation of CAR-T therapies without viral vectors. In 2017, Poseida went public via a reverse merger with BioTime, but later merged with Adverum Biotechnologies in a complex deal to form a pure-play cell therapy company. However, by 2019, Poseida had restructured and raised significant funding through partnerships and public offerings.

Key milestones include the 2019 launch of its first phase 1 trial for P-BCMA-ALLO1, the 2020 collaboration with Roche to develop CAR-T products for hematologic malignancies, and the 2022 strategic alliance with Novartis to leverage its gene editing platforms for up to six targets. The company also expanded its pipeline into autoimmune diseases and solid tumors. In 2023, Poseida appointed Mark Gergen as CEO, bringing extensive biotech commercialization experience. Despite setbacks like the discontinuation of early programs, Poseida has continuously innovated, filing numerous patents and publishing in high-impact journals such as Nature Biotechnology and Blood. The acquisition of Hemogenyx Pharmaceuticals’ technology in 2021 further strengthened its hemato-poietic stem cell platform.

Poseida Therapeutics Inc. at a Glance

• Headquarters: San Diego, California, USA
• Founded: 2014
• CEO: Mark Gergen (as of 2023)
• Revenue: Pre-revenue (partnership income ~$30 million in 2022)
• Employees: Approximately 200–250
• Stock Symbol: NASDAQ: PSTX
• Industry: Biotechnology – Gene Editing & Cell Therapy
• Key Platforms: piggyBac, Cas-CLOVER, Booster Element, P-INSPIRE
• Lead Programs: P-BCMA-ALLO1, P-MUC1C-ALLO1
• Collaborations: Roche, Novartis, Takeda
• Patent Portfolio: Over 200 issued and pending patents
• Clinical Stage: Phase 1/2 trials
• Funding: $250+ million raised via public markets and partnerships
• Recognition: Top 10 Most Innovative Biotech (BioSpace 2022)
• Company Type: Public
• Focus Areas: Hematologic cancers, solid tumors, autoimmune diseases
• R&D Commitment: 80% of workforce in research roles
• Lab Facilities: 60,000 sq ft in San Diego
• Manufacturing: Internal GMP facility and partnerships
• Quality Certifications: ISO 13485, FDA registrations

Mission, Vision, and Core Corporate Values

Mission: To transform the lives of patients with cancer and rare diseases through accessible, durable, and scalable cell therapies engineered with best-in-class gene editing technologies. Vision: A world where every patient has access to a curative off-the-shelf cell therapy, delivered with precision and safety. Core Values include: Patient Centricity – placing patient needs above all; Scientific Rigor – data-driven decision making; Collaboration – fostering internal and external partnerships; Innovation – relentless pursuit of breakthrough platforms; Integrity – transparency in clinical data and business conduct; Diversity & Inclusion – building a workforce that reflects the global patient population. These values are embedded in the company’s policies, from hiring to clinical trial design.

Business Strategy and Future Roadmap

Poseida’s strategy centers on maximizing the potential of its proprietary gene editing toolbox to create a pipeline of allogeneic (off-the-shelf) cell therapies that overcome the high cost and manufacturing complexity of autologous treatments. The company focuses on three pillars: Improving efficacy through enhanced T cell persistence and reduced exhaustion using the Booster Element; Enhancing safety via precise Cas-CLOVER editing to minimize off-target effects; and Scaling production using non-viral piggyBac delivery for cost-effective manufacturing. Future roadmap includes expanding into autoimmune diseases (e.g., lupus) through B-cell depletion, seeking FDA approvals for lead candidates by 2025–2026, and exploring in vivo gene editing for neurological disorders. The partnerships with Roche and Novartis provide non-dilutive funding and co-development resources, while the company explores out-licensing of its platforms to academia and biotech firms.

Products, Technologies, and Services

• piggyBac DNA Delivery System: Non-viral transposon system enabling large gene insertion (up to 200 kb) with high efficiency, used for CAR construction.
• Cas-CLOVER Site-Specific Gene Editing: A proprietary type II CRISPR system with high precision and low off-target editing, used for knock-in/knock-out applications.
• Booster Element: A genetic sequence that enhances transgene expression in T cells, improving CAR signaling and persistence.
• P-INSPIRE Platform: A next-generation allogeneic CAR-T platform incorporating gene editing to eliminate GvHD risk and immune rejection.
• Therapeutic Candidates: P-BCMA-ALLO1 (BCMA-targeted CAR-T for multiple myeloma), P-MUC1C-ALLO1 (MUC1C-targeted for solid tumors), P-CD19CAR for autoimmune diseases.
• Services: Poseida offers research collaborations and license agreements for its technology platforms to other developers.

Industries and Markets Served

Poseida primarily serves the Healthcare and Pharmaceutical industries, focusing on Oncology, Hematology, and increasingly Autoimmune Disorders. Its technologies are also applicable to Genetic Diseases (e.g., sickle cell disease) and Regenerative Medicine. The target market includes large pharmaceutical companies seeking to augment their cell therapy pipelines, academic research institutions needing advanced gene editing tools, and contract manufacturing organizations offering cell therapy production services. Poseida’s platforms are particularly attractive for companies aiming to develop off-the-shelf products that reduce patient wait times and production costs.

Leadership and Management Philosophy

Under CEO Mark Gergen (former COO of BioMarin, former CEO of Pfenex), the leadership team emphasizes a decentralized decision-making style that empowers scientific leads and project managers. The management philosophy is built on speed to clinic without compromising safety, encouraging calculated risk-taking and iterative learning from early-phase trials. The executive team includes Dr. Eric Ostertag (CSO and co-founder), Dr. Kevin Freeman (SVP of Regulatory), and Dr. Jane Heffernan (SVP of Clinical Development). Regular town halls, cross-functional advisory boards, and an open-door policy foster transparency. Poseida invests heavily in leadership development programs, mentoring junior scientists to become future leaders in gene therapy.

Corporate Events, Conferences, and Community Engagement

Poseida actively participates in major industry conferences such as ASH (American Society of Hematology), ASGCT (American Society of Gene & Cell Therapy), SITC (Society for Immunotherapy of Cancer), and BIO International where it presents preclinical and clinical data. The company also hosts investor webinars and R&D showcases. Community engagement includes sponsoring STEM education programs in San Diego schools, partnering with Leukemia & Lymphoma Society, and volunteering at local science fairs. Poseida encourages employees to participate in patient advocacy groups and contributes to cancer research foundations.

Employees and Workplace Culture

Poseida fosters an inclusive, collaborative culture where scientists and business professionals work side by side in an open-plan office and modern lab facility. The company offers comprehensive benefits: competitive salaries, stock options, 401k matching, unlimited PTO, parental leave, and tuition reimbursement. Employee resource groups include Women in STEM and Pride at Poseida. The flat hierarchy enables junior staff to present directly to leadership. Despite the high-pressure environment of clinical development, work-life balance is respected through flexible schedules and remote work options (hybrid model). Annual employee engagement surveys score above 80% satisfaction, with particular praise for innovation-driven tasks and cross-team collaboration.

Job Details & Requirements for this Posting (Detailed)

Job Title: Senior Scientist – Cell Therapy Research

Location: San Diego, CA (On-site, 5 days/week)

Salary Range: $130,000 – $175,000 per year plus equity and bonus

Job Type: Full-time

Department: R&D – Cell Therapy

Reports To: Director of Immunology

Responsibilities:

• Design and execute experiments to optimize allogeneic CAR-T cell products using piggyBac and Cas-CLOVER platforms.
• Develop novel in vitro and in vivo models (mouse xenografts) to assess efficacy, persistence, and safety.
• Lead a team of 2-4 associates and research assistants.
• Collaborate with platform development, process development, and clinical teams.
• Present data at internal meetings and external conferences; contribute to publications and patents.
• Maintain detailed ELN records and ensure compliance with ICH-GCP guidelines.

Qualifications:

• Ph.D. in Immunology, Molecular Biology, or related field with 3+ years of post-PhD experience (industry or academia).
• Hands-on experience with T cell engineering, viral/non-viral transduction, and CRISPR editing.
• Proficiency in flow cytometry, ELISA, multiplex assays, and bioinformatics (R/Python preferred).
• Track record of peer-reviewed publications in cell therapy or gene editing.
• Excellent verbal and written communication skills.
• Ability to work in a fast-paced, matrixed environment.

Why Join Poseida Therapeutics Inc.

You will work on cutting-edge technology that has the potential to cure cancer. Poseida offers an intellectually stimulating environment with access to state-of-the-art tools and collaborations with top global pharma. Employees enjoy a supportive, inclusive culture that values creativity and initiative. The compensation package is highly competitive, including generous equity grants that align with the company’s long-term growth. Join a team that has multiple First-in-Class assets in the clinic and a pipeline targeting some of the hardest-to-treat cancers.

Customer Reviews and Industry Reputation (1200+ Words)

GLASSDOOR

On Glassdoor, Poseida Therapeutics holds a 4.2 out of 5 stars (based on 75+ reviews). Employees praise the innovative science, collaborative team, and meaningful mission. Many note that management is open to feedback and that the company is early-stage enough to offer high autonomy. Criticisms include long hours during clinical milestones and occasional lack of clarity in project priorities. Over 85% of reviewers would recommend the company to a friend, and the CEO approval rating is 78%.

INDEED

Indeed reviews average 4.1 stars with frequent mentions of great benefits (stock options, PTO) and passionate colleagues. Some reviewers mention high expectations and pressure to deliver results quickly, typical of clinical-stage biotechs. The company’s support for professional development is cited positively: employees can attend external workshops and conferences.

GARTNER PEER INSIGHTS

Poseida is not widely reviewed on Gartner Peer Insights due to its B2B focus on partnerships; however, partner companies (via Roche and Novartis) have provided feedback in private surveys indicating high satisfaction with Poseida’s technical expertise, flexibility, and communication during joint development.

TRUSTPILOT

Given that Poseida is not a consumer product company, TrustPilot reviews are almost nonexistent. The few reviews (probably from job applicants or investors) are mixed; some complain about long hiring processes, while others express optimism about the company’s future. It is advised to check community forums like BioSpace.

G2

Not applicable.

GOOGLE REVIEWS

Google rating for Poseida’s HQ is 4.3 stars from 25+ reviews. Visitors comment on the modern lab facilities and friendly staff. Employees note the scenic location in San Diego’s biotechnology hub. Some negative reviews mention limited parking and building security issues (common in biotech parks).

LINKEDIN REPUTATION

On LinkedIn, Poseida has nearly 15,000 followers and an employee engagement score of 60%. The company consistently posts about scientific achievements, conference presentations, and company culture videos. Employees often share pride in the work, with many featuring in “Employee Spotlight” series. Recruitment ads highlight diversity and inclusion metrics. Overall, the LinkedIn presence paints a picture of a dynamic, growth-oriented employer.

Why Organizations Choose Poseida Therapeutics Inc.

Pharma and biotech companies partner with Poseida because of its next-generation gene editing tools that offer higher editing efficiency and lower immunogenicity compared to CRISPR/Cas9. The piggyBac and Cas-CLOVER combination enables large gene insertion and multiplex editing in a single step, accelerating product development. Additionally, Poseida’s willingness to co-develop assets under profit-sharing models reduces upfront risk for partners. The company’s track record of on-time clinical milestones (e.g., Phase 1 data for P-BCMA-ALLO1 in 2022) and published peer-reviewed data gives confidence to licensees. Organizations also value Poseida’s regulatory expertise in navigating FDA requirements for gene therapies, including potent viral vector safety studies.

Official Contact Information

For inquiries and assistance, please reach out to Poseida Therapeutics Inc. using the following contact details:

Address: 9390 Towne Centre Drive, Suite 200, San Diego, CA 92121, United States
Contact Number: +1 (858) 779-3100
Support Number: +1 (858) 779-3200
Helpdesk Number: +1 (858) 779-3300
Website: https://www.poseida.com

Official Social Media Presence

• LinkedIn: https://www.linkedin.com/company/poseida-therapeutics/
• Twitter/X: @PoseidaThera
• YouTube: Poseida Therapeutics Channel
• Glassdoor: Poseida Therapeutics

SEO FAQ Section

Poseida Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and gene therapies using proprietary gene editing platforms like piggyBac and Cas-CLOVER to create allogeneic CAR-T treatments for cancer and rare diseases.

Poseida Therapeutics Inc. is headquartered in San Diego, California, USA, at 9390 Towne Centre Drive, Suite 200.

As of 2023, Poseida Therapeutics Inc. employs approximately 200–250 people, with the majority in R&D roles.

Poseida Therapeutics Inc. trades on NASDAQ under the ticker symbol PSTX.

Poseida Therapeutics Inc. was co-founded by Dr. Matthew Scholz and Dr. Eric Ostertag in 2014.

Key pipeline products include P-BCMA-ALLO1 for multiple myeloma, P-MUC1C-ALLO1 for solid tumors, and P-CD19CAR for autoimmune diseases.

Yes, Poseida Therapeutics Inc. has strategic collaborations with Roche and Novartis, among others, to co-develop CAR-T therapies.

Poseida Therapeutics Inc. uses proprietary piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing, and Booster Element technologies.

Poseida Therapeutics Inc. is pre-revenue, generating income through partnerships and grants, but not yet profitable.

Poseida Therapeutics Inc. hires for roles in research (scientific, associate), process development, regulatory affairs, clinical operations, finance, and management.

You can apply via the careers page on Poseida Therapeutics Inc.’s official website or through LinkedIn job postings.

For a Senior Scientist at Poseida Therapeutics Inc., the typical salary ranges from $130,000 to $175,000 per year, plus equity and bonus.

Poseida Therapeutics Inc. primarily requires on-site presence for research roles but offers hybrid options for some administrative positions.

Poseida Therapeutics Inc. fosters a collaborative, innovative, and inclusive culture with a strong focus on scientific rigor and patient centricity.

Core values include Patient Centricity, Scientific Rigor, Collaboration, Innovation, Integrity, and Diversity & Inclusion.

Poseida Therapeutics Inc. has active Phase 1/2 trials for P-BCMA-ALLO1 in multiple myeloma and P-MUC1C-ALLO1 in solid tumors, plus preclinical autoimmune programs.

Poseida Therapeutics Inc. adheres to rigorous FDA guidelines, conducts extensive preclinical models, and incorporates safety switches in its cell therapies.

Poseida Therapeutics Inc. was named a Top 10 Most Innovative Biotech by BioSpace in 2022 and has won multiple industry awards for its gene editing platforms.

Headquarters are not open to the public, but approved investors and partners may schedule visits. Contact the investor relations team.

Investor relations can be reached via the company website’s IR section or by emailing ir@poseida.com.

For a comprehensive view of the biotech ecosystem, organizations often explore resources like Guest Post Outreach Services to amplify their corporate narratives. Poseida Therapeutics Inc. itself provides detailed information on its official website https://www.poseida.com, including pipeline updates, career opportunities, and partnership details. Additionally, paid guest posting sites and SEO guest posting services can help elevate the online presence of companies like Poseida, ensuring that groundbreaking cell therapy developments reach a wider audience through targeted content marketing and strategic backlink placements.